Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc
Bullboard Posts
User Avatar Image
(37)
•••
Comment by wagyusteakon Nov 13, 2020 10:23am
126 Views
Post# 31894607

RE:RE:RE:Does anyone sell today?? Let me buy your shares @ $1-$3

RE:RE:RE:Does anyone sell today?? Let me buy your shares @ $1-$3
Snowballgrowth wrote:
Benedict16th wrote: The market is so inpressed of this MNGT team Q3 report. The share price shot up by hge 5 cents.  OMG ...The exit door is getting closer and closer for mngt. Ne new deal, not guidence and 400 millions idle. If  six years ago you blind folded  a monkey with darts shooting on a board to selcts investments to buy for a billion dollars worth the monkey would have done a hell of a lot better with a 10% yearly return 


The reps can't go to see the doctors


he doesn't read the reports or listen to the earnings call. All he cares is the stock price. If it goes up, it means good. If it goes down, it means bad. The stock price tells him everything he needs to know.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities